Gilead dips as ‘strong’ earnings outweighed by high expectations for new HIV drug

Shares fell as much as 6% in after-hours trading, a decline one analyst guessed may be because Yeztugo’s trajectory isn’t matching investors’ sky-high hopes.

Continue reading →